Literature DB >> 27096136

Innovative Hypofractionated Stereotactic Regimen Achieves Excellent Local Control with No Radiation Necrosis: Promising Results in the Management of Patients with Small Recurrent Inoperable GBM.

Angela Jia1, Susan C Pannullo2, Shlomo Minkowitz3, Shoshana Taube1, Jenghwa Chang1, Bhupesh Parashar1, Paul Christos4, A Gabriella Wernicke1.   

Abstract

Management of recurrent glioblastoma multiforme (GBM) remains a challenge. Several institutions reported that a single fraction of ≥ 20 Gy for small tumor burden results in excellent local control; however, this is at the expense of a high incidence of radiation necrosis (RN). Therefore, we developed a hypofractionation pattern of 33 Gy/3 fractions, which is a radiobiological equivalent of 20 Gy, with the aim to lower the incidence of RN. We reviewed records of 21 patients with recurrent GBM treated with hypofractionated stereotactic radiation therapy (HFSRT) to their 22 respective lesions. Sixty Gy fractioned external beam radiotherapy was performed as first-line treatment. Median time from primary irradiation to HFSRT was 9.6 months (range: 3.1 - 68.1 months). In HFSRT, a median dose of 33 Gy in 11 Gy fractions was delivered to the 80% isodose line that encompassed the target volume. The median tumor volume was 1.07 cm3 (range: 0.11 - 16.64 cm3). The median follow-up time after HFSRT was 9.3 months (range: 1.7 - 33.6 months). Twenty-one of 23 lesions treated (91.3%) achieved local control while 2/23 (8.7%) progressed. Median time to progression outside of the treated site was 5.2 months (range: 2.2 - 9.6 months). Progression was treated with salvage chemotherapy. Five of 21 patients (23.8%) were alive at the end of this follow-up; two patients remain disease-free. The remaining 16/21 patients (76.2%) died of disease. Treatment was well tolerated by all patients with no acute CTC/RTOG > Grade 2. There was 0% incidence of RN. A prospective trial will be underway to validate these promising results.

Entities:  

Keywords:  gliomastoma multiforme; hypofractionated; small recurrent tumor; stereotactic radiotherapy

Year:  2016        PMID: 27096136      PMCID: PMC4835149          DOI: 10.7759/cureus.536

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  38 in total

1.  Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas.

Authors:  Shannon E Fogh; David W Andrews; Jon Glass; Walter Curran; Charles Glass; Colin Champ; James J Evans; Terry Hyslop; Edward Pequignot; Beverly Downes; Eileen Comber; Mitchell Maltenfort; Adam P Dicker; Maria Werner-Wasik
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

2.  Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.

Authors:  G Minniti; V Armosini; M Salvati; G Lanzetta; P Caporello; M Mei; M F Osti; R Enrici Maurizi
Journal:  J Neurooncol       Date:  2010-11-05       Impact factor: 4.130

3.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.

Authors:  June L Chan; Susan W Lee; Benedick A Fraass; Daniel P Normolle; Harry S Greenberg; Larry R Junck; Stephen S Gebarski; Howard M Sandler
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

4.  Radiosurgery as part of the initial management of patients with malignant gliomas.

Authors:  J S Loeffler; E Alexander; W M Shea; P Y Wen; H A Fine; H M Kooy; P M Black
Journal:  J Clin Oncol       Date:  1992-09       Impact factor: 44.544

5.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

6.  Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy?

Authors:  Emmanouil Fokas; Ulrich Wacker; Markus W Gross; Martin Henzel; Elitsa Encheva; Rita Engenhart-Cabillic
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

7.  Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.

Authors:  Toshihiko Iuchi; Kazuo Hatano; Takashi Kodama; Tsukasa Sakaida; Sana Yokoi; Koichiro Kawasaki; Yuzo Hasegawa; Ryusuke Hara
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-01       Impact factor: 7.038

8.  Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme.

Authors:  Nathan S Floyd; Shiao Y Woo; Bin S Teh; Charlotte Prado; Wei-Yuan Mai; Todd Trask; Philip L Gildenberg; Paul Holoye; Mark E Augspurger; L Steven Carpenter; Hsin H Lu; J Kam Chiu; Walter H Grant; E Brian Butler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

9.  Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma.

Authors:  Dirk Vordermark; Oliver Kölbl; Klemens Ruprecht; Giles H Vince; Klaus Bratengeier; Michael Flentje
Journal:  BMC Cancer       Date:  2005-05-30       Impact factor: 4.430

10.  Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience.

Authors:  Patrizia Ciammella; Ala Podgornii; Maria Galeandro; Nunziata D'Abbiero; Anna Pisanello; Andrea Botti; Elisabetta Cagni; Mauro Iori; Cinzia Iotti
Journal:  Radiat Oncol       Date:  2013-09-25       Impact factor: 3.481

View more
  1 in total

1.  Neuroimaging classification of progression patterns in glioblastoma: a systematic review.

Authors:  Rory J Piper; Keerthi K Senthil; Jiun-Lin Yan; Stephen J Price
Journal:  J Neurooncol       Date:  2018-03-30       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.